GATWICK, England--(BUSINESS WIRE)-- Systagenix Wound Management (Gatwick, UK) today announced the appointment of Joe Woody as a member of the company’s Board of Directors. Woody is currently President of Covidien’s Vascular Therapies business and was previously Global President of Smith and Nephew Advanced Wound Care.
“We are delighted that Joe has agreed to join the Board of Directors of Systagenix,” said Ernest Waaser, Chief Executive Officer. “His strategic vision, experience in growing global medical device businesses and specific expertise in the wound care industry will be great assets to our Board as we build Systagenix into the world leader in products and services for the diagnosis and targeted treatment of chronic wounds.”
“I am honored to join Ernest and an esteemed group of industry leaders on the Systagenix board. I look forward to having a positive impact on the company’s decision-making processes and strategies to deliver world-class wound care products,” said Woody.
Woody is responsible for Covidien’s portfolio of vascular products, composed of three broad product categories: Venous Vascular (dialysis catheters, compression devices, deep vein thrombosis and chronic venous insufficiency prevention and intervention devices); Peripheral Vascular (peripheral arterial stents, balloons and atherectomy); and Neurovascular (brain aneurysm embolic coils and flow diversion, thrombectomy and liquid embolics). Woody was instrumental in Covidien’s acquisition of ev3, Inc., a $450 million company dedicated to the endovascular treatment of peripheral vascular and neurovascular diseases. He joined Covidien in May 2009 after holding positions of increasing responsibility for Smith & Nephew, Inc.; Alliance Imaging, Inc.; EMC, Acuson and General Electric Medical Systems.
Home of the Let’s Heal® family of brands, Systagenix is a leading global supplier of advanced wound care solutions. More recently, the company announced its commitment to be the first to enter the field of wound diagnostics, by introducing the first point of care test to detect elevated levels of protease activity, which is a key marker for wound healing, as highlighted by several published articles and international consensus documents. Once available, this will be the entry point of the Let’s Heal® system, making it a unique approach within the world of wound care.
Formed via the acquisition of Johnson & Johnson’s advanced wound care business in 2008, the company supplies over 20 million wound dressings per month into over 100 countries worldwide for use in treating hard-to-heal acute and chronic wounds. Its leading edge product portfolio includes ADAPTIC TOUCH®, TIELLE®, SILVERCEL® NON-ADHERENT, ACTISORB®, INADINE®, PROMOGRAN®, and PROMOGRAN PRISMA®.
Information on Systagenix wound care can be found at www.systagenix.com.
Vicky Stoakes, +44 (0)7747 534 519
KEYWORDS: United Kingdom United States Europe Asia Pacific North America Central America South America Canada New York
INDUSTRY KEYWORDS: Health Biotechnology Hospitals Medical Devices Pharmaceutical Other Health Medical Supplies Nursing Managed Care